- AMD3465hexahydrobroMide
-
- $0.00 / 1KG
-
2022-01-15
- CAS:185991-07-5
- Min. Order: 1KG
- Purity: 97.4%
- Supply Ability: 100 tons
|
| | AMD 3465 (*Hexahydrobromide*) Basic information |
| Product Name: | AMD 3465 (*Hexahydrobromide*) | | Synonyms: | AMD 3465 (*Hexahydrobromide*);AMD 3465;AMD 3465 (hydrobroMide);1-(2-Pyridinyl)-N-[4-(1,4,8,11-tetraazacyclotetradecan-1-ylMethyl)benzyl]MethanaMine;AMD3465 R10406hexahydrobromide;N-[[4-(1,4,8,11-Tetraazacyclotetradec-1-ylmethyl)phenyl]methyl]-2-pyridinemethanamine hexahydrobromide;AMD3465,98%;CS-810 | | CAS: | 185991-07-5 | | MF: | C24H39BrN6 | | MW: | 491.52 | | EINECS: | | | Product Categories: | | | Mol File: | 185991-07-5.mol |  |
| | AMD 3465 (*Hexahydrobromide*) Chemical Properties |
| Melting point | >200°C (dec.) | | storage temp. | -20°C | | solubility | DMSO (Slightly), Methanol (Very Slightly), Water (Slightly) | | form | powder | | color | white to light brown |
| | AMD 3465 (*Hexahydrobromide*) Usage And Synthesis |
| Uses | AMD 3465 is a CXCR4 antagonist and in combination with monoclonal antibody, was shown to be potentially effective in reducing tumor growth and increasing survival in patient with B cell lymphoma | | Biochem/physiol Actions | AMD3465 is also termed as{N-[1,4,8,11-tetraazacyclotetradecanyl-1,4-phenylenebis(methylene)]-2-(aminomethyl)pyridine}. It controls oncogenic signaling and invasiveness in vitro. It inhibits breast cancer growth and metastasis in vivo. As a chemokine receptor 4 (CXCR4) antagonist, AMD3465 is ten times more efficient than bicyclam AMD3100. | | storage | Store at -20°C |
| | AMD 3465 (*Hexahydrobromide*) Preparation Products And Raw materials |
|